Risk factors of node metastasis in cervical carcinoma

Purpose of investigation: To investigate the metastatic risk factors of pelvic lymph nodes in patients with cervical carcinoma in Stage Ia2 and IIa2. Materials and Methods: The clinic pathologic parameters in 337 patients with Stage Ia2-IIa2 cervical carcinoma were retrospectively analyzed. The risk factors for pelvic lymph node metastasis were evaluated by the way of univariate X² statistic analysis and binary logistic regression analysis. Results: The lymph nodes metastasis rate was 11.87% (40/337). Single variable analysis showed that age, clinical stage, the size of tumor ≥ four cm, depth of stromal invasion ≥ 2/3, lymph-vascular space involvement (LVSI), and parametrial extension were related to the metastasis of lymph nodes. Multivariate analysis showed that the size of tumor, depth of stromal invasion, LVSI, and parametrial extension were independent risk factors. Conclusion: Patients with tumor size ≥ four cm, stromal invasion ≥ 2/3, LVSI, and parametrial extension were at high risk of lymph node metastasis.

Cervical cancer; Lymph nodes; Metastasis; Risk factor.

[1] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D.: “Global cancer statistics”. CA Cancer J. Clin., 2011, 61, 69.

[2] Niikura H., okamoto S., Otsuki T., Yoshinaga K., Utsunomiya H., Nagase S., et al.: “Prospectinve study of sentinel lymph node biopsy without further pelvic lymph Adeneomy in patients with sentinel lymph nodenegative cervical cancer”. Int. J. Gynecol. Cancer, 2012, 22, 1244.

[3] Okazawa M., Mabuchi S., Isohashi F., Suzuki O., Ohta Y., Fujita M., et al.: “The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy”. Int. J. Gynecol Cancer, 2012, 22, 490.

[4] Li D., Cai J., Kuang Y., Cao J., Wang Z.: “Surgical-pathologic risk factors of pelvic lymph node metastasis in stage IB1-IIB cervical cancer”. Acta Obstet. Gynecol. Scand., 2012, 91, 802.

[5] Ouldamar L., Marret H., Acker O., Barillot I., Body G.: “Unusual localizations of sentinel lymph nodes in early stage cervical cancer: a review”. Surg. Oncol., 2012, 21, 153.

[6] Gadducci A., Tei G., Barsotti C., Tana R., Fanucchi A., Orlandini C., et al.: “Clinicopathological variables predictive of clinical outcome in patients with FIGO stage IB2-IIB cervical cancer treats with cisplatin- based neoadjuvant chemotherapy followed by radical hysterectomy”. Anticancer Res., 2010, 30, 201.

[7] Gien L.T., Beauchemin M.C., Thomas G.: “Adenocarcinoma: a unique cervical cancer”. Gynecol. Oncol., 2010, 116, 140.

[8] Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J., et al.: “American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer”. CA Cancer J. Clin., 2012, 62, 147.

[9] Koleli I.K., Ozdogan E., Sariibrahim B., Ozturk LB., Karateke A.: “Prognostic factors affecting lymph node involvement in cervical cancer”. Eur. J. Gynaecol. Oncol., 2014, 35, 428.

[10] Turan T., Yildirim B.A., Tulunay G., Boran N., Kose M. F.: “Prognostic effect of different cut-off values (20mm, 30mm and 40mm) for clinical tumor size in FIGO stage IB cervical cancer”. Surg. Oncol., 2010, 19, 106.

[11] Yanaranop M., Sathapornteera N., Nakrangsee S.: “Risk factors of pelvic lymph node metastasis in cervical adenocarcinoma fpllowing radical hysterectomy andpelvic lymphadenectomy”. J. Med. Assoc. Thai, 2014, 97, 87.

[12] Pallavi V.R., Mukherjee G., Ramesh C., Bafna U.D.: “Relationshiop between lymph node metastases and histopathological parametersin carcinoma cervix:multivariate analysis”. J. Obstet. Gynaecol., 2012, 32, 78.

[13] Epstein E., Testa A., Gaurilcikas A., Di L.A., Ameye L., Atstupenaite V., et al.: “Early-stage cervical cancer:Tumor delineation by magnetic resonance imaging and ultrasound-A European multicenter trial”. Gynecol. Oncol., 2013, 128, 449.

[14] Yamaguchi S.,Nishimura R.,Yaegashi N.,Kiguchi K.,Kita T., et al.: “Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065)”. Oncol. Rep., 2012, 28, 487.

[15] Lee Y.Y., Choi C.H., Kim T.J., Lee J.W., Kim B.G., Lee J.H., et al.: “A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA”. Gynecol. Oncol., 2010, 120, 439.

[16] Katanyoo K., Sanguanrungsirikul S., Manusirivithaya S.: “Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer”. Gynecol. Oncol., 2012, 125, 292.

[17] Nogueira-Rodrigues A., Ferreira C.G., Bergmann A., de Aguiar S.S., Thuler L.C.: “Comparison of adenocarcinoma (ACA) and squamous cell carcinoma (SCC) of the uterine cervix in a sub-optimally screened cohort: a population-based epidemiologic study of 51,842 women in Brazil”. Gynecol. Oncol., 2014, 135, 292.

[18] Intaraphet S., Kasatpibal N., Siriaunkgul S., Sogaard M., Patumanond J., Khunamornpong S., et al.: “Prognostic impact of histology in patients with cervical squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma”. Asian Pac. J. Cancer Rev., 2013, 14, 5355.